Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D1W8RK
|
|||
| Drug Name |
PN-943
|
|||
| Drug Type |
peptide
|
|||
| Indication | Ulcerative colitis [ICD-11: DD71; ICD-9: 556] | Phase 2 | [1] | |
| Company |
Protagonist Therapeutics Newark, CA
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Integrin alpha-4/beta-7 (ITGA4/B7) | Target Info | Antagonist | [2] |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT04504383) A Phase 2 Randomized, Double-blind, Placebo-controlled, Parallel-group, Multi-center Study to Evaluate the Safety and Efficacy of Oral PN-943 in Subjects With Moderate to Severe Active Ulcerative Colitis. U.S.National Institutes of Health. | |||
| REF 2 | Single- and Multiple-Dose Pharmacokinetics and Pharmacodynamics of PN-943, a Gastrointestinal-Restricted Oral Peptide Antagonist of alpha4beta7, in Healthy Volunteers. Clin Pharmacol Drug Dev. 2021 Nov;10(11):1263-1278. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.